News | Mobile C-Arms | November 30, 2020

Ziehm Imaging and Therenva Jointly Present Mobile Hybrid Solution

The solution, presented at RSNA20, features image fusion and endovascular 3D navigation

The solution, presented at RSNA20, features image fusion and endovascular 3D navigation

November 30, 2020 — At this year's virtual RSNA congress, Ziehm Imaging showcases its leading portfolio of mobile C-arms and advanced imaging solutions. Highlights on display include the Ziehm Vision RFD Hybrid Edition in combination with Therenva’s EndoNaut solution for advanced endovascular 3D intraoperative navigation as well as the Ziehm Vision RFD 3D, one of the most successful 3D mobile imaging solutions in the market with an installed base of close to 1,000 systems. The virtual booth offers a guided tour, product videos and much more on the proven Ziehm Imaging C-arm portfolio as well as the latest generation of Orthoscan mini C-arms.

Driving OR integration through deeper soft- and hardware integration

Earlier this year, Ziehm Imaging acquired Therenva, a French-based leading developer of planning and imaging software for cardiovascular procedures. By combining the Ziehm Vision RFD Hybrid Edition and Therenva’s EndoNaut solution, physicians benefit from advanced interventional imaging with 3D intraoperative navigation for optimal guidance in endovascular interventions. The solution provides decisive information for planning and localization of devices with intraoperative 3D navigation, providing physicians with more confidence, accuracy and visual comfort during stent and graft interventions.

The two partners now put a strong focus on co-developing new solutions to provide enhanced image-based decision support systems in the cardiovascular field, and potentially further clinical areas. Through deeper soft- and hardware integration, Ziehm Imaging and Therenva will jointly drive OR integration and set new standards in image fusion and 3D navigation to provide clinicians with powerful yet seamless workflows.

More than one decade of 3D imaging expertise – installed base of more than 1,500 3D C-arms

15 years after the introduction of its first mobile 3D mobile C-arm, Ziehm Imaging marks an important milestone: “Having reached the mark of a total installed base of 1,500 3D C-arms this year makes us extremely proud”, said Martin Törnvik, Vice President Global Sales & Marketing at Ziehm Imaging. “The fact that we are close to having 1,000 systems of our flagship model Ziehm Vision RFD 3D in the market, is a great motivation for us to keep driving our innovation efforts to continuously set new standards in mobile C-arm technology and intraoperative 3D navigation.”

The Ziehm Vision RFD 3D features cutting-edge CMOS technology, bundling 2D and 3D functionality for greater intraoperative control, reducing the need for postoperative CT scans and costly corrective surgeries. The versatile mobile C-arm is ideally suited for high-end orthopedic, trauma and spinal interventions as well as for highly specialized maxillofacial and cochlear procedures.

First mini C-arm family for pediatric imaging

With the family of TAU systems, Orthoscan is first on the market to present mini C-arms approved for pediatrics. Thanks to an intelligent dose concept with an optimized dose filter, the TAU family can not only be used in adult hand and foot surgery, but now also for intraoperative monitoring of pediatric procedures. Besides the standard version Orthoscan TAU 1512, the new product family includes two premium categories featuring pulsed fluoroscopy: Orthoscan TAU 1515 (15 cm x 15 cm detector) and TAU 2020 (20 cm x 20 cm detector).

Visit the Ziehm Imaging and Orthoscan booth on the RSNA virtual exhibition floor: ebooth.ziehm.com

Related Content

News | Artificial Intelligence | May 11, 2021
May 11, 2021 — Whiterabbit, an AI technology company focused on early...
National Imaging Solutions, a recognized leader in medical imaging and radiology solutions, announced it has acquired DynaRad — the oldest manufacturer of portable X-ray systems in the US. This new investment will allow National Imaging Solutions to support its customers by supplying them with DynaRad portable X-ray machines, including a mobile field X-ray device using nanotube technology.
News | Radiology Business | May 11, 2021
May 11, 2021 — ...
3D aMRI not only provides a stunning look inside the "beating brain", but it can also measure this physiological motion in all directions. Here, the amplitude of brain motion is overlayed for each brain slice and orientation in 3D. Image credit: 3D aMRI method outlined in Abderezaei et al. Brain Multiphysics (2021); Terem et al. Magnetic Resonance in Medicine (2021).

3D aMRI not only provides a stunning look inside the "beating brain", but it can also measure this physiological motion in all directions. Here, the amplitude of brain motion is overlayed for each brain slice and orientation in 3D. Image credit: 3D aMRI method outlined in Abderezaei et al. Brain Multiphysics (2021); Terem et al. Magnetic Resonance in Medicine (2021).

News | Magnetic Resonance Imaging (MRI) | May 06, 2021
May 6, 2021 — Magnetic Resonance Imaging
Research finds that a commonly used risk-prediction model for lung cancer does not accurately identify high-risk Black patients who could benefit from early screening

Getty Images

News | Lung Imaging | May 05, 2021
May 5, 2021 — Lung cancer is the third most common cance
After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by

After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by N. Galldiks et al., Research Center Juelich, Juelich, Germany.

News | PET Imaging | May 05, 2021
May 5, 2021 — For patients with brain metastases, amino acid ...